BIIB

Business Context and Reporting Period

Company: Biogen Idec Inc. (formed by the merger of IDEC Pharmaceuticals Corporation and Biogen, Inc. on November 12, 2003).

Reporting Period: Quarterly period ended September 30, 2004 (10-Q).

Business Overview: The company focuses on oncology and immunology. Key commercial products include AVONEX (multiple sclerosis), RITUXAN and ZEVALIN (B-cell non-Hodgkin's lymphoma), and AMEVIVE (psoriasis). The company is also developing ANTEGREN (natalizumab) for multiple sclerosis and Crohn's disease.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased significantly compared to the prior year periods ($138.5 million for 3 months and $379.3 million for 9 months in 2003). This is primarily due to the inclusion of Biogen's products (AVONEX and AMEVIVE) for the full period in 2004, whereas 2003 results only included them post-merger (Nov-Dec 2003).
• Profitability Decline: Despite revenue growth, the company reported a net loss of $3.6 million for the nine months ended September 30, 2004, compared to net income of $115.5 million in the same period in 2003. This was driven by high amortization of acquired intangible assets ($267.2 million) and inventory fair value adjustments from the merger.
• Expense Increases: Research and Development (R&D) expenses rose 310% year-over-year for the nine-month period, and Selling, General, and Administrative (SG&A) expenses rose 436%, largely attributable to the consolidation of Biogen's operations.
• Inventory Write-downs: The company recorded $21.0 million in inventory write-downs for the nine months ended September 30, 2004, related to AVONEX, ZEVALIN, and AMEVIVE due to quality specifications or demand estimates.

Guidance, Outlook, and Risks

• Product Pipeline: ANTEGREN applications for MS (U.S. and EU) and Crohn's disease (EU) have been submitted. The FDA designated ANTEGREN for Priority Review and Accelerated Approval for MS.
• Manufacturing Expansion: Significant capital projects are underway, including a large-scale manufacturing facility in Oceanside, CA (estimated total cost $480 million), a campus in San Diego, CA ($170 million), and a facility in Hillerød, Denmark ($340 million).
• Stock Repurchase: The company completed a $698.4 million repurchase of 12 million shares in the first nine months of 2004. A new program to repurchase up to 20 million shares was authorized in October 2004.
• Legal Risks:
  • Columbia University Litigation: Ongoing dispute regarding patent royalties. The court dismissed a 2003 action for lack of jurisdiction after Columbia covenanted not to sue a subsidiary, but a new 2004 action was filed seeking declaratory judgment on patent invalidity.
  • Medicaid Litigation: Named in lawsuits regarding Average Wholesale Price reporting and Medicaid rebates. Some claims were dismissed, but others regarding state laws and unjust enrichment remain pending.
• Financial Risks: The company relies heavily on AVONEX and RITUXAN (approx. 93% of Q3 revenue). Future results depend on the successful launch of ANTEGREN and the commercialization of pipeline products.

Investor Verification Checklist

• Merger Accounting Impact: Verify the duration and magnitude of non-cash charges related to the Biogen merger (amortization of intangibles and inventory step-up) to understand the true operating cash generation.
• ANTEGREN Approval Status: Monitor FDA and EU regulatory decisions on ANTEGREN, as its launch is critical for future growth beyond current core products.
• Inventory Quality: Review future quarters for continued inventory write-downs, particularly for AVONEX and ZEVALIN, which impacted margins in Q3 2004.
• Legal Outcomes: Track the resolution of the Columbia University patent litigation and the Medicaid pricing lawsuits, as adverse rulings could result in significant royalty liabilities or fines.
• Capital Expenditures: Assess the progress and cost overruns of major manufacturing facilities (Oceanside, San Diego, Denmark) which represent significant cash outflows.